- Home
- STOK vs KOD Comparison
STOK vs KOD Comparison
Compare STOK & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STOK | KOD |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | STOK | KOD |
|---|---|---|
| Price | $32.40 | $23.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $34.50 | $28.29 |
| AVG Volume (30 Days) | 685.0K | ★ 709.8K |
| Earning Date | 03-17-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $205,632,000.00 | N/A |
| Revenue This Year | $430.24 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $44.52 | ★ N/A |
| Revenue Growth | ★ 1128.17 | N/A |
| 52 Week Low | $5.35 | $1.92 |
| 52 Week High | $38.69 | $31.18 |
Technical Indicators
Market Signals| Indicator | STOK | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 40.15 |
| Support Level | $30.33 | $20.88 |
| Resistance Level | $34.47 | $25.30 |
| Average True Range (ATR) | 2.02 | 2.02 |
| MACD | 0.32 | -0.60 |
| Stochastic Oscillator | 84.32 | 14.51 |
Price Performance
Historical ComparisonAbout STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.